
Tucatinib and Trastuzumab Demonstrates Safety, Efficacy in HER2-Mutated Breast Cancer
Tucatinib (Tukysa; Array BioPharma) and trastuzumab (Herceptin; Genentech) demonstrated clinically meaningful antitumor activity with durable responses and favorable tolerability in heavily pretreated patients with human epidermal growth factor receptor 2 …